LABORATORY AND CLINICAL STUDIES OF RU 28965 IN DERMATOLOGY

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement4; pp. 530 - 533
• Main Authors: SHIMOZUMA, MICHIRO, ABE, MASANORI, NOGITA, TOSHITATSU, MATSUYAMA, TOMOHIKO, ISHIBASHI, YASUMASA
• Format: Journal Article
• Language: English; Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement4_530

We studied RU 28965, a new macrolide antibiotic, experimentally and clinically. Minimal inhibitory concentrations of RU 28965 against S.aureus, Staphylococcus sp., P.acnes, P.asaccharolyticus, B.cereus, P.aeruginosa and S.agalactiae isolatid from clinical specimens were measured. In a pharmacokinetic study, the concentrations of RU 28965 in serum and cutaneous tissues were estimated after oral administration of 150mg tablets to 6 patients who underwent skin biopsy or excision. Serum concentrations ranged from 0.9-22.4μg/ml. Cutaneous tissue concentrations ranged from 0.37-5.10μg/g. In a clinical study RU 28965 tablets were administered orally to 11 patients with various forms of suppurative dermatosis: folliculitis (3), furunculosis (3), infectious atheroma (3), acne conglobata (1) and secondary infection (1). The overall efficacy was 81.8%. No significant side-effects or abnormal clinical-laboratory findings were noted except for slight eosinophilia in one case.